Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

The OncFive: Top Oncology Articles for the Week of 8/24

August 30th 2025

The FDA has cleared a 3-month subcutaneous depot formulation of leuprolide mesylate in prostate cancer, gedatolisib NDA is under review in breast cancer, and more.

Dr Hanna on the Pharmacokinetic Profile of Micvotabart Pelidotin in HNSCC

August 27th 2025

Glenn J. Hanna, MD, discusses the preliminary antitumor activity and manageable safety profile of micvotabart pelidotin in head and neck squamous cell carcinoma.

PDS0101 Plus Pembrolizumab Yields Durable Survival Benefit in HPV16+ HNSCC

August 25th 2025

Versamune HPV plus pembrolizumab improved OS vs historical data with pembrolizumab in HPV16-positive metastatic HNSCC with a CPS of at least 1.

Health Canada Authorizes Perioperative Pembrolizumab in Resectable, Locally Advanced HNSCC

August 13th 2025

Perioperative pembrolizumab has received the green light for use in combination with radiotherapy with or without cisplatin in PD-L1–positive HNSCC.

OncLive’s July EMA Regulatory Recap: Key EU Approvals in Oncology

August 6th 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in July 2025.

FDA Outlines Next Steps for Development of Eftilagimod Alfa in PD-L1–Negative HNSCC

August 5th 2025

The FDA provided feedback on next steps of development for eftilagimod alfa in PD-L1–negative recurrent/metastatic head and neck squamous cell carcinoma.

CUE-101 Plus Pembrolizumab Yields 50% ORR in HPV+ HNSCC With Low PD-L1 Expression

July 16th 2025

In patients with HPV16-positive HNSCC, CUE-101 plus pembrolizumab generated 2 complete responses and a 12-month overall survival rate of 88%.

European Commission Approves First-Line Tislelizumab Plus Chemo for Metastatic Nasopharyngeal Carcinoma

July 10th 2025

The European Commission has approved tislelizumab plus gemcitabine/cisplatin for adults with recurrent or metastatic nasopharyngeal carcinoma.

The OncFive: Top Oncology Articles for the Week of 6/29

July 5th 2025

The FDA grants approval to sunvozertinib in NSCLC and linvoseltamab in myeloma and removes REMS requirements for approved CAR T-cell therapies.

OncLive’s FDA Approval Report: The Regulatory Rundown for June 2025

July 1st 2025

Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.

Dr Uppaluri on the Implications of the FDA Approval of Perioperative Pembrolizumab in Resectable, Locally Advanced HNSCC

July 1st 2025

Ravindra Uppaluri, MD, PhD, discusses the FDA approval of pembrolizumab in the neoadjuvant and adjuvant setting for resectable, locally advanced HNSCC.

Expert Investigators Highlight Cross-Cancer Updates for Fellows From the 2025 AACR Annual Meeting

July 1st 2025

Experts in the fields of lung, head and neck, HER2+ breast, and hematologic cancers discuss notable updates for fellows from the 2025 AACR Annual Meeting.

2025 Giants of Cancer Care: OncLive® Honors 13 Cancer Care Pioneers

June 30th 2025

OncLive® showcases 13 cancer care pioneers, who have won the 2025 Giants of Cancer Care award.

The OncFive: Top Oncology Updates for the Week of 6/8

June 14th 2025

The FDA has approved new options in head and neck cancer, lung cancer, and bladder cancer—and more from OncLive this week.

Dr Adkins on the FDA Approval of Pembrolizumab for Neoadjuvant/Adjuvant Treatment in Resectable, Locally Advanced HNSCC

June 12th 2025

Douglas R. Adkins, MD, discusses the FDA approval of pembrolizumab for neoadjuvant and adjuvant treatment in resectable, locally advanced head and neck squamous cell carcinoma.

FDA Approves Perioperative Pembrolizumab for Resectable, Locally Advanced HNSCC

June 12th 2025

The FDA has approved perioperative pembrolizumab adjuvant radiotherapy in resectable locally advanced HNSCC.

Postoperative Nivolumab Plus SOC Extends DFS in Resected, High-Risk Head and Neck Cancer

June 1st 2025

Patients with locally advanced, high-risk head and neck cancer showed significantly improved DFS with adjuvant nivolumab plus cisplatin and radiotherapy.

CHMP Recommends EU Approval of Frontline Tislelizumab/Chemo for Metastatic Nasopharyngeal Carcinoma

May 27th 2025

The EMA’s CHMP recommended the EU approval of first-line tislelizumab plus chemotherapy for adults with recurrent or metastatic nasopharyngeal carcinoma.

FDA Approval of Penpulimab Expands Treatment Options in Recurrent/Metastatic Non-Keratinizing NPC

May 15th 2025

Aditya Shreenivas, MD, MS, discusses the FDA approval of penpulimab for recurrent/metastatic non-keratinizing NPC.

Giants of Cancer Care® Announces the 13th Annual Class of Inductees

May 7th 2025

OncLive announces the inductees of the 13th annual Giants of Cancer Care recognition program.